Trial Profile
Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD (CAIAC)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms CAIAC
- 12 Jul 2021 Status changed to discontinued.
- 17 Sep 2018 New trial record